A few things on my mind:
A very strange — and painful — year in biotech calls for an unusual nominee to occupy a spot on my annual list of the best CEOs, which is why I’m looking at Catalyst Biosciences’ Nassim Usman.
Usman and the Catalyst board are working to wind down the long-troubled company’s operations and sell off assets. On Wednesday, Catalyst announced that it would be returning approximately $65 million to shareholders. The funds came from the sale of a portfolio of drug candidates to Vertex Pharmaceuticals.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
